Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

Hye Won Lee, Jun Yong Park, Taegon Hong, Min Soo Park, Sang Hoon Ahn

Research output: Contribution to journalShort surveypeer-review

3 Citations (Scopus)

Abstract

The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4

Original languageEnglish
Pages (from-to)3043-3045.e1
JournalClinical Gastroenterology and Hepatology
Volume18
Issue number13
DOIs
Publication statusPublished - 2020 Dec

Bibliographical note

Funding Information:
Funding Supported by GC Pharma Co Ltd.

Publisher Copyright:
© 2020 AGA Institute

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection'. Together they form a unique fingerprint.

Cite this